Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 202 current clinical trials in our China register. 132 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Capecitabine, Sintilimab and Carboplatin. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting13265%
Not yet open3618%
Active, closed2211%
By invitation126%

Trials by phase

Phase 28241%
Observational3718%
Not applicable3015%
Phase 3168%
Phase EARLY_PHASE1136%
Phase 1126%
Phase 1/284%
Phase 2/331%
Phase 410%

Clinical trials sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences

202 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study NCT07657494 · ClinicalTrials.gov ↗ · Aggressive Lymphoma	Not applicable	Recruiting	2024-07	China
Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver Metastases NCT07027605 · ClinicalTrials.gov ↗ · Colorectal Liver Metastasis (CRLM)	Observational	Recruiting	2025-01	China
Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC NCT07618078 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC) Drug: Capecitabine	Observational	Recruiting	2026-01	China
Chemoradiotherapy in Unresectable Esophageal Cancer NCT04278287 · ClinicalTrials.gov ↗ · Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel Drugs: Albumin-Bound Paclitaxel, Cisplatin, Nab-paclitaxel	Phase 1/2	Recruiting	2019-10	China
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer NCT07166003 · ClinicalTrials.gov ↗ · Lung Cancer, Non-Small Cell, Immunotherapy	Observational	Recruiting	2025-04	China
Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma NCT06644352 · ClinicalTrials.gov ↗ · Siewert Type II Adenocarcinoma of Esophagogastric Junction	Not applicable	Recruiting	2022-07	China
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC NCT06897046 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC), II-IIIB Drugs: Carboplatin, Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2025-07	China
A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening NCT07395479 · ClinicalTrials.gov ↗ · Advanced Malignant Tumours	Phase EARLY_PHASE1	Recruiting	2025-11	China
Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors NCT07349160 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase EARLY_PHASE1	Recruiting	2026-01	China
Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma NCT06163729 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma (Siewert II-III) Drugs: Camrelizumab, Oxaliplatin, Paclitaxel	Phase 2	Recruiting	2022-08	China
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis. NCT06839547 · ClinicalTrials.gov ↗ · Advanced Breast Cancer Brain Metastasis	Observational	Recruiting	2025-03	China
Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer NCT07040098 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC)	Phase 2	Recruiting	2025-06	China
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo NCT07239245 · ClinicalTrials.gov ↗ · Resectable Hepatocellular Carcinoma With High Risk of Recurrence	Phase 2	Recruiting	2025-11	China
Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors NCT06346041 · ClinicalTrials.gov ↗ · Neoplasms	Phase EARLY_PHASE1	Recruiting	2024-04	China
Surgery or Chemoradiotherapy for Cervical Esophageal Cancer NCT05327517 · ClinicalTrials.gov ↗ · Cervical Esophageal Cancer	Not applicable	Recruiting	2022-04	China
A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma NCT07063888 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy, Narrow Margin	Phase 2	Recruiting	2025-05	China
Prospective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain NCT07657390 · ClinicalTrials.gov ↗ · Cancer Pains	Phase 1/2	Recruiting	2025-12	China
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients NCT06202001 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer Drugs: Bevacizumab, Trifluridine/Tipiracil	Phase 1/2	Recruiting	2022-10	China
Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction NCT07084519 · ClinicalTrials.gov ↗ · Breast Cancer, Breast Reconstruction, Radiation Oncology	Phase 3	Recruiting	2026-03	China
Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer NCT07352280 · ClinicalTrials.gov ↗ · Colo-rectal Cancer (dMMR/MSI-H CRC)	Observational	Recruiting	2026-02	China
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02) NCT05183074 · ClinicalTrials.gov ↗ · Prostate Cancer, Radiotherapy Side Effect, Magnetic Resonance-linac	Not applicable	Recruiting	2021-02	China
Super-Hypofractionated Partial Breast Irradiation NCT06615466 · ClinicalTrials.gov ↗ · Breast Cancer, Radiotherapy Side Effect	Not applicable	Recruiting	2022-04	China
Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC NCT07120282 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC)	Phase 2	Recruiting	2025-10	China
Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ NCT06808971 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma	Phase 2	Recruiting	2025-02	China
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma NCT06087068 · ClinicalTrials.gov ↗ · Thyroid Cancer, Surgery, Recurrence	Phase 2	Recruiting	2022-08	China
MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer NCT07156058 · ClinicalTrials.gov ↗ · Biliary Tract Cancer Drug: Capecitabine	Not applicable	Recruiting	2023-01	China
An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors NCT06038461 · ClinicalTrials.gov ↗ · Neuroendocrine Tumors	Phase 1/2	Recruiting	2023-09	China
A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer NCT06776861 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Observational	Recruiting	2024-09	China
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis NCT07203729 · ClinicalTrials.gov ↗ · HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis Drug: Trastuzumab Rezetecan	Phase 2	Recruiting	2026-03	China
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer NCT06086457 · ClinicalTrials.gov ↗ · Esophageal Neoplasms	Phase 3	Recruiting	2024-02	China
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer NCT07689851 · ClinicalTrials.gov ↗ · Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma Drug: SHR-1701	Phase 2	Recruiting	2026-07	China
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients NCT07043894 · ClinicalTrials.gov ↗ · Solid Tumors, Hematological Tumor, Children Drug: Romiplostim N01	Phase 2	Recruiting	2025-12	China
Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01) NCT05224934 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma, Retroperitoneal Sarcoma, Radiotherapy Side Effect	Not applicable	Recruiting	2022-01	China
Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy NCT07014202 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	2025-06	China
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials NCT06612632 · ClinicalTrials.gov ↗ · Cancer Drug: Toripalimab	Phase 1/2	Recruiting	2024-05	China
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors NCT06926751 · ClinicalTrials.gov ↗ · Solid Tumors, Children, Adolescent Drugs: Filgrastim, Telpegfilgrastim	Phase 2	Recruiting	2025-06	China
Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC NCT07724223 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC) Drug: Fruquintinib	Phase 2	Recruiting	2026-01	China
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression NCT05749289 · ClinicalTrials.gov ↗ · SSTR Positive Tumors	Phase 2/3	Recruiting	2022-12	China
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers NCT06255197 · ClinicalTrials.gov ↗ · Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma	Observational	Recruiting	2019-11	China
A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer NCT06082180 · ClinicalTrials.gov ↗ · Thyroid Cancer, Recurrence	Phase 3	Recruiting	2022-07	China
Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy NCT07668037 · ClinicalTrials.gov ↗ · Non-Small Cell Carcinoma of Lung, Immunotherapy, Advanced Non-Small Cell Lung Cancer	Observational	Recruiting	2026-05	China
Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer NCT07156045 · ClinicalTrials.gov ↗ · Prostate Cancer Castration-resistant Prostate Cancer Drug: Anti-PSMA CAR-NK	Phase EARLY_PHASE1	Recruiting	2025-09	China
A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer NCT07026669 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Observational	Recruiting	2025-01	China
Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT) NCT07110090 · ClinicalTrials.gov ↗ · Thrombocytopenia, Cancer	Phase 1	Recruiting	2025-08	China
Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases NCT06848842 · ClinicalTrials.gov ↗ · Colorectal Liver Metastases Drug: Ivonescimab	Phase 2	Recruiting	2025-09	China
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer NCT06789679 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma	Phase 2	Recruiting	2025-01	China
Detecting CREPT in Urine for Bladder Cancer Diagnosis and Monitoring NCT07514897 · ClinicalTrials.gov ↗ · Bladder Cancer	Observational	Recruiting	2026-03	China
Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer NCT06993506 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Recurrence, Metastasis Drug: Sacituzumab tirumotecan	Observational	Recruiting	2026-05	China
Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. NCT06771609 · ClinicalTrials.gov ↗ · Advanced Triple-negative Breast Cancer	Phase 2	Recruiting	2024-09	China
Goal-directed Enteral Nutritional Perioperative Management NCT06510543 · ClinicalTrials.gov ↗ · Esophagus Cancer	Not applicable	Recruiting	2024-03	China
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma NCT05188859 · ClinicalTrials.gov ↗ · Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced Drugs: Anlotinib, Cisplatin, Pemetrexed	Phase 2	Recruiting	2024-09	China
Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer NCT06908668 · ClinicalTrials.gov ↗ · HER2-Negative Locally Advanced Breast Cancer	Phase 2	Recruiting	2025-03	China
A Study of ES014 in Subjects With Advanced Solid Tumors NCT06543056 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drug: ES014	Phase 2	Recruiting	2024-11	China
Personalized KSX01-TCRT in Patients With Advanced Solid Tumors NCT06150365 · ClinicalTrials.gov ↗ · Refractory Solid Tumors, Relapsed Solid Tumors	Phase EARLY_PHASE1	Recruiting	2023-11	China
Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01） NCT05167994 · ClinicalTrials.gov ↗ · Sarcoma,Soft Tissue, Extremity, Trunk Drug: Anlotinib hydrochloride	Phase 2	Recruiting	2020-05	China
The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy NCT07187154 · ClinicalTrials.gov ↗ · Esophageal Cancer	Not applicable	Recruiting	2026-05	China
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer NCT05983107 · ClinicalTrials.gov ↗ · HR+/HER2- Advanced Breast Cancer, Targeted Therapy Drugs: Chidamide, Everolimus	Phase 2	Recruiting	2023-07	China
Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery NCT06483698 · ClinicalTrials.gov ↗ · Lung Cancer	Observational	Recruiting	2024-03	China
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma NCT06417892 · ClinicalTrials.gov ↗ · Gastric Cancer Drugs: Albumin paclitaxel, Fruquintinib, PD-1inhibitor	Observational	Recruiting	2024-04	China
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. NCT07443397 · ClinicalTrials.gov ↗ · Whole-Brain Radiotherapy Drug: Anlotinib	Phase 3	Recruiting	2025-08	China
Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer NCT06757621 · ClinicalTrials.gov ↗ · Breast Carcinoma	Phase 3	Recruiting	2024-10	China
Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC) NCT06793813 · ClinicalTrials.gov ↗ · Stage IVB Lung Cancer, Non-Squamous	Phase 2	Recruiting	2024-01	China
PLATFORM Study of Precision Medicine for Rare Tumors NCT04423185 · ClinicalTrials.gov ↗ · Rare Tumor Drugs: Alectinib, Almonertinib, Atezolizumab	Phase 2	Recruiting	2020-08	China
Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors NCT07656116 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	2026-01	China
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ NCT06761846 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma Drug: Sintilimab	Phase 2	Recruiting	2025-01	China
Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma NCT07692152 · ClinicalTrials.gov ↗ · Anal Squamous Cell Carcinoma, Limited-stage Drugs: Capecitabine, Mitomycin, Sintilimab	Phase 3	Recruiting	2026-03	China
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer NCT06413992 · ClinicalTrials.gov ↗ · Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic Drugs: Camrelizumab, Carboplatin, Fluzoparib	Phase 2	Recruiting	2024-05	China
Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study NCT06350370 · ClinicalTrials.gov ↗ · Colorectal Cancer	Not applicable	Recruiting	2019-01	China
Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer NCT07034742 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma	Phase EARLY_PHASE1	Recruiting	2025-06	China
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H) NCT06146946 · ClinicalTrials.gov ↗ · Rectal Cancer	Not applicable	Recruiting	2023-12	China
Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC NCT06371586 · ClinicalTrials.gov ↗ · Gastric Cancer, Diffuse Type Carcinoma Drug: Albumin paclitaxel	Phase 2	Recruiting	2024-03	China
Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC NCT07110103 · ClinicalTrials.gov ↗ · SCLC, SCLC, Extensive Stage	Phase 2	Recruiting	2025-10	China
CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC NCT07383246 · ClinicalTrials.gov ↗ · Medullary Thyroid Carcinoma	Phase 3	Recruiting	2025-08	China
Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer NCT06904677 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC), Neoadjuvant Therapy, Proteomics	Observational	Recruiting	2025-05	China
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer NCT05886439 · ClinicalTrials.gov ↗ · Lung Cancer Drugs: Durvalumab, Pembrolizumab, Tislelizumab	Phase 1/2	Recruiting	2023-05	China
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor NCT05761366 · ClinicalTrials.gov ↗ · Malignancy	Phase 2	Recruiting	2022-10	China
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM NCT06543069 · ClinicalTrials.gov ↗ · Malignant Peritoneal Mesothelioma, Advanced	Phase 2	Recruiting	2024-01	China
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC NCT07232654 · ClinicalTrials.gov ↗ · LOCALLY ADVANCED CERVICAL CANCERS Drugs: Cisplatin, Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2025-11	China
MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy NCT02988921 · ClinicalTrials.gov ↗ · Esophagus Cancer, Esophagogastric Junction Cancer	Not applicable	Recruiting	2016-10	China
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib NCT07033819 · ClinicalTrials.gov ↗ · Ovarian Cancer Drug: Apatinib	Phase 2	Recruiting	2025-06	China
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study NCT06958627 · ClinicalTrials.gov ↗ · HER2 Positive Breast Cancer, Pyrotinib Treatment Drug: Pyrotinib	Phase 2/3	Recruiting	2024-04	China
Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors. NCT06928922 · ClinicalTrials.gov ↗ · Advanced Lung Cancer, Lung Metastasis	Phase EARLY_PHASE1	Recruiting	2025-02	China
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer NCT06421376 · ClinicalTrials.gov ↗ · Esophageal Cancer, Immunotherapy, Induction Therapy Drug: Cardonilizumab	Phase 2	Recruiting	2024-05	China
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. NCT07249879 · ClinicalTrials.gov ↗ · Relapsed/Refractory Small Cell Lung Cancer	Phase 1	Recruiting	2026-03	China
An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors NCT07743749 · ClinicalTrials.gov ↗ · Renal Tumor, Kidney Neoplasm	Observational	Recruiting	2021-01	China
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC NCT06277180 · ClinicalTrials.gov ↗ · Medullary Thyroid Cancer, Prositron Emission Tomography, Fibroblast Activation Protein Inhibitor	Not applicable	Recruiting	2023-10	China
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma NCT06410651 · ClinicalTrials.gov ↗ · Esophageal Cancer, Nimotuzumab, Chemoradiotherapy	Phase 2	Recruiting	2023-03	China
Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer NCT07057102 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Observational	Recruiting	2025-01	China
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer NCT06154538 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Carcinoma Drug: Folfox	Phase 2	Recruiting	2023-11	China
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC) NCT07298239 · ClinicalTrials.gov ↗ · Prostate Cancer Castration-resistant Prostate Cancer Drug: Anti-PSMA CAR-NK	Phase EARLY_PHASE1	Recruiting	2025-12	China
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy NCT06084897 · ClinicalTrials.gov ↗ · Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb Drug: Carboplatin	Phase 2	Recruiting	2023-10	China
Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer NCT05345860 · ClinicalTrials.gov ↗ · Early-stage Breast Cancer	Not applicable	Recruiting	2022-03	China
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults NCT06761417 · ClinicalTrials.gov ↗ · Solid Tumors, Children, Adolescents Drugs: Anlotinib, Capecitabine, Mitoxantrone liposome	Phase 2	Recruiting	2025-01	China
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis NCT06389422 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab Drug: Pembrolizumab	Phase 2	Recruiting	2024-05	China
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer NCT06197581 · ClinicalTrials.gov ↗ · Breast Cancer, Familial Male, Radiotherapy; Complications, Chemotherapeutic Toxicity	Not applicable	Recruiting	2024-01	China
Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites NCT07435701 · ClinicalTrials.gov ↗ · Ovarian Neoplasms Malignant, Ascites	Phase 1/2	Recruiting	2026-01	China
Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients NCT05762900 · ClinicalTrials.gov ↗ · Breast Cancer, Radiotherapy Side Effect	Phase 2	Recruiting	2022-10	China
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer NCT04821778 · ClinicalTrials.gov ↗ · Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation Drug: Nimotuzumab	Phase 3	Recruiting	2002-01	China
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC NCT06170710 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	2023-12	China
NV-001 in the Treatment of Advanced Solid Tumors NCT06051760 · ClinicalTrials.gov ↗ · Malignant Neoplasm	Phase 1	Recruiting	2023-12	China

Showing the 100 most recently updated of 202 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials

90 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 50 more in the trial list above.

Conditions in Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials

254 conditions

By trial register

Register	Trials	Recruiting
Clinical trials in China	202	132

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Hoffmann-La Roche	10
Ruijin Hospital	10
Xijing Hospital	9

Sponsors with the most current trials registered for this condition.

Questions about Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials

How many clinical trials does Cancer Institute and Hospital, Chinese Academy of Medical Sciences sponsor?

Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 202 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials recruiting?

Yes. 132 of its 202 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Cancer Institute and Hospital, Chinese Academy of Medical Sciences testing?

Its current trials name 90 drugs and biologicals as interventions. The most frequent are Capecitabine (7), Sintilimab (7), Carboplatin (5), Anlotinib (4) and Iparomlimab and Tuvonralimab (4). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences clinical trials